LncRNA SNHG16 as a potential biomarker and therapeutic target in human cancers

• Main Authors: Yuhang Xiao, Ta Xiao, Wei Ou, Zhining Wu, Jie Wu, Jinming Tang, Bo Tian, Yong Zhou, Min Su, Wenxiang Wang
• Format: Article
• Language: English
• Published: BMC 2020-09-01
• Series: Biomarker Research
• Subjects: SNHG16; Long non-coding RNA; Human cancer; Mechanism; Biomarker
• Online Access: http://link.springer.com/article/10.1186/s40364-020-00221-4

Abstract Long non-coding RNAs (lncRNAs) represent an important class of RNAs comprising more than 200 nucleotides, which are produced by RNA polymerase II. Although lacking an open reading framework and protein-encoding activity, lncRNAs can mediate endogenous gene expression by serving as chromatin remodeler, transcriptional or post-transcriptional modulator, and splicing regulator during gene modification. In recent years, increasing evidence shows the significance of lncRNAs in many malignancies, with vital roles in tumorigenesis and cancer progression. Moreover, lncRNAs were also considered potential diagnostic and prognostic markers in cancer. The lncRNA small nuclear RNA host gene 16 (SNHG16), found on chromosome 17q25.1, represents a novel tumor-associated lncRNA. SNHG16 was recently found to exhibit dysregulated expression in a variety of malignancies. There are growing evidence of SNHG16’s involvement in characteristics of cancer, including proliferation, apoptosis, together with its involvement in chemoresistance. In addition, SNHG16 has been described as a promising diagnostic and prognostic biomarker in cancer patients. The current review briefly summarizes recently reported findings about SNHG16 and discuss its expression, roles, mechanisms, and diagnostic and prognostic values in human cancers.